Posted by on Feb 24, 2018 in Leukemia | 0 comments

In a nutshell This study examined how treatment with ibrutinib (Imbruvica), rituximab (Rituxan), and bendamustine (Treanda) impacts quality of life in chronic lymphocytic leukemia (CLL) patients. Factors such as fatigue, physical functioning, and well-being were all improved among those patients with the lowest scores before treatment. Some background...

Read More